Paul Little
Chief Executive Officer Atrogi
Seminars
Wednesday 28th October 2026
Panel & Audience Discussion: Evaluating Oral, Injectable & DNA Delivery Methods to Align Modality Selection with Clinical Performance & Commercial Scale
4:15 pm
- Comparing modality trade-offs in potency, safety and half-life between oral small molecules and injectable peptide therapeutics to guide smarter development decisions
- Exploring how advances in oral delivery and next-generation formats to expand treatment options beyond injectables
- Discussing the manufacturing strengths and pitfalls of oral, DNA and injectable peptide therapies to align delivery mechanisms with commercial viability and faster routes to market
Thursday 29th October 2026
Targeting B2-Receptors to Develop Obesity Therapeutics That Preserve Muscle Mass
9:30 am
- Stimulating the B2 adrenergic receptor to combat obesity
- Leveraging Atrogi’s GPCR discovery platform to discovery precise targets to manage metabolism
- Highlighting ATR-339 clinical data to demonstrate durable, muscle maintaining therapeutics
